Citation Impact
Citing Papers
Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ)
2001 StandoutScience
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
2010
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
A New, Practical One‐Pot Synthesis of Unprotected Sulfonimidamides by Transfer of Electrophilic NH to Sulfinamides
2017
Recent advances in natriuretic peptides in congestive heart failure
2004
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Nitric oxide/redox-based signalling as a therapeutic target for penile disorders
2006
Discovery of Riociguat (BAY 63‐2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension
2009
Sulfoximines: A Neglected Opportunity in Medicinal Chemistry
2013
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
2002
Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide
2002
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
2016
Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation
2004 Standout
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
2006 Standout
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
2005
Characterization of the First Potent and Selective PDE9 Inhibitor Using a cGMP Reporter Cell Line
2005
BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts
2009
Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery
2016
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential
2006
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
2008
Topographical distribution of neurons containing endothelin type A receptor in the rat brain
1997
Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury
2008
Pharmacological actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vitro studies
2002
cGMP in the Vasculature
2008
Expression of the cGMP‐specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains
2007
Erectile Dysfunction and Lower Urinary Tract
2008
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
Prevention of VTE in Nonsurgical Patients
2012 Standout
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti‐FXa assays
2014 StandoutNobel
Heme-based sensors: defining characteristics, recent developments, and regulatory hypotheses
2004
Nitric oxide-sensitive guanylyl cyclase: structure and regulation
2004
Kynurenine is an endothelium-derived relaxing factor produced during inflammation
2010
Antithrombotic Therapy for VTE Disease
2012 Standout
Aptamers as therapeutics
2010 Standout
cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
2010 Standout
Role of Oxidative Modifications in Atherosclerosis
2004 Standout
ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis
2007 Standout
The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord
2006
Emerging drug profile: cyclin-dependent kinase inhibitors
2013
N‐Cyano Sulfoximines: COX Inhibition, Anticancer Activity, Cellular Toxicity, and Mutagenicity
2012
Nitrates and no release: contemporary aspects in biological and medicinal chemistry
2004
A survey of yeast genomic assays for drug and target discovery
2010
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
2019
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Effects of Iron Supplementation and Depletion on Hypoxic Pulmonary Hypertension
2009 StandoutNobel
Allometric scaling of xenobiotic clearance: Uncertainty versus universality
2001
Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity1
2007
Inflammation in atherosclerosis
2002 StandoutNature
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Effect of cerivastatin sodium, a new inhibitor of HMG‐CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
1999
Complex I Is the Major Site of Mitochondrial Superoxide Production by Paraquat
2007 Standout
Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase
2003
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
2019
Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice
1994 Standout
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations
2013
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
2009
Nitric oxide signaling: no longer simply on or off
2006
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
2019 Standout
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics
2009
The increase in pulmonary arterial pressure caused by hypoxia depends on iron status
2008 StandoutNobel
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor
2005
Comparative pharmacology of rosuvastatin
2003
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
2010 StandoutNobel
Chronic thromboembolic pulmonary hypertension
2014
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
2019
TRPV1 and TRPA1 Mediate Peripheral Nitric Oxide-Induced Nociception in Mice
2009 StandoutNobel
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
2015
Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor.
1991
Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3′,5′-Cyclic Monophosphate–Dependent Protein Kinase
2003
Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes.
1992
Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.
1993 Standout
Effect of Hypercholesterolemia on Expression and Function of Vascular Soluble Guanylyl Cyclase
2002
Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy
2002 StandoutNobel
Chronic Kidney Disease Diagnosis and Management
2019 Standout
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
2008
Effects of endothelins on signal transduction and proliferation in human melanocytes.
1991
Factor Xa Inhibitors: Next-Generation Antithrombotic Agents
2010
Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity
2018
Inflammation in Atherosclerosis
2012 Standout
SuFEx Chemistry of Thionyl Tetrafluoride (SOF4) with Organolithium Nucleophiles: Synthesis of Sulfonimidoyl Fluorides, Sulfoximines, Sulfonimidamides, and Sulfonimidates
2018 StandoutNobel
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Recent advances in the trifluoromethylation methodology and new CF3-containing drugs
2014
Pulmonary Arterial Hypertension
2006
Regulation of Nitric Oxide-Sensitive Guanylyl Cyclase
2003
Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling
2006
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
2006
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney Disease
2017
Inhibition of Phosphodiesterase Type 5 by the Activator of Nitric Oxide–Sensitive Guanylyl Cyclase BAY 41-2272
2004
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions
2005 Standout
NO-sensitive guanylyl cyclase and NO-induced feedback inhibition in cGMP signaling
2005
Enantioselective Imidation of Sulfides via Enzyme-Catalyzed Intermolecular Nitrogen-Atom Transfer
2014 StandoutNobel
Inflammation and Atherosclerosis
2002 Standout
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro
2001
Recent Advances in Endothelin Research on Cardiovascular and Endocrine Systems.
1994
Sulfoximine: Eine vernachlässigte Chance in der medizinischen Chemie
2013
Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy
1990
Chronic Thromboembolic Pulmonary Hypertension
2006 Standout
Relative sensitivity of soluble guanylate cyclase and mitochondrial respiration to endogenous nitric oxide at physiological oxygen concentration
2007
Prolactin: Structure, Function, and Regulation of Secretion
2000 Standout
Tracking functions of cGMP-dependent protein kinases (cGK)
2005
Cinaciguat (BAY 58–2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure
2009
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase.
2004
Growth Factors and Cancer
1991 StandoutScience
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Pharmacological Activation of Soluble Guanylate Cyclase Protects the Heart Against Ischemic Injury
2009
Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy.
1994 StandoutNobel
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
2009 Standout
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)
2007
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
Chronic regulation of arterial blood pressure by ANP: role of endogenous vasoactive endothelial factors
1998
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
2020
Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation
2007
Nitric Oxide–Independent Vasodilator Rescues Heme-Oxidized Soluble Guanylate Cyclase From Proteasomal Degradation
2009
Pathophysiology and Pharmacological Treatment of Insulin Resistance*
2000
NO-Independent, Haem-Dependent Soluble Guanylate Cyclase Stimulators
2008
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Works of Wolfram Steinke being referenced
BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
2012
NO-independent regulatory site on soluble guanylate cyclase
2001 Nature
Preclinical review of cerivastatin sodium—a step forward in HMG-CoA reductase inhibition
1998
125I-endothelin-1 and 125I-big endothelin-1 in rat tissues: autoradiographic localization and receptor binding
1991
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
2014
NO‐ and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle
2002
Pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rats and dogs
2005
NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272
2001
Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C]acarbose to rats and dogs.
1989
Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.
1997
BAY W 6228
1994
Biotransformation of cerivastatin in mice, rats, and dogs in vivo.
1998
Autoradiographic Localization of [125I]Endothelin-1 and [125I]Atrial Natriuretic Peptide in Rat Tissue
1989
Autoradiographic localization of 125J-endothelin in rat tissues.
1989